Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass

NCT ID: NCT02830789

Last Updated: 2017-06-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2017-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates whether calcium citrate or calcium carbonate are the optimal supplement to treat secondary hyperparathyroidism following Roux-en-Y gastric bypass operation.

Half of the participants will be randomized to receive calcium citrate, while the other half will receive calcium carbonate. The study will be double blinded.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Roux-en-Y Gastric Bypass Hyperparathyroidism, Secondary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Calcium Carbonate

1 tablet Unikalk Forte + 1 placebo tablet by mouth three times daily equal to 1200 mg elementary calcium and 57 µg Vitamin D3

Group Type EXPERIMENTAL

Calcium Carbonate

Intervention Type DIETARY_SUPPLEMENT

Placebo

Intervention Type DIETARY_SUPPLEMENT

Tablet manufactured to mimic a calcium carbonate tablet

Roux-en-Y gastric bypass

Intervention Type PROCEDURE

Roux-en-Y gastric bypass surgery at least 12 months before study inclusion

Calcium Citrate

2 tablets Unikalk Citrat by mouth three times daily equal to 1200 mg elementary calcium and 60 µg Vitamin D3

Group Type EXPERIMENTAL

Calcium Citrate

Intervention Type DIETARY_SUPPLEMENT

Roux-en-Y gastric bypass

Intervention Type PROCEDURE

Roux-en-Y gastric bypass surgery at least 12 months before study inclusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Calcium Carbonate

Intervention Type DIETARY_SUPPLEMENT

Calcium Citrate

Intervention Type DIETARY_SUPPLEMENT

Placebo

Tablet manufactured to mimic a calcium carbonate tablet

Intervention Type DIETARY_SUPPLEMENT

Roux-en-Y gastric bypass

Roux-en-Y gastric bypass surgery at least 12 months before study inclusion

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Unikalk Forte Unikalk Citrat

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Roux-en-Y gastric bypass operation ≥12 months ago
* Parathyroid hormone \> 6.9 pmol/l
* Vitamin D \> 50 nmol/l
* P-Calcium \[1.18-1.32\] mmol/l

Exclusion Criteria

* Liver disease
* Renal disease
* Hypercalcemia
* Untreated thyroid disease
* Parathyroid disease except secondary hyperparathyroidism
* Use of diuretics, bisphosphonates, calcitonin, teriparatide, oral corticosteroids, anabolic steroids, calcimimetics, lithium, strontium, denosumab or anticonvulsants within 1 year of inclusion
* abusing alcohol
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Aarhus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lene Ring Madsen

PhD student, MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Enodocrinology and Internal Medicine, Aarhus University Hospital

Aarhus, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20160610

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Iron Absorption Trial
NCT02228902 COMPLETED PHASE4